The patients were suffering from persistent ventricular premature contractions (VPCs), presenting as ventricular bigeminy — a condition in which nearly every alternate heartbeat is abnormal.

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

Comparing the structure and function of the heart’s right and left ventricles. How the 'armpit of Kansas City' landed the ...

A new study from the University of Pennsylvania has found that a thicker right side of the heart may be linked to a higher ...

Raelyn Gordon has brought hope to the area through her optimism and fighting spirit, demonstrated by her ongoing fight ...

"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...

PETALING JAYA: The health ministry has made history with the successful implantation of the country’s first left ventricular ...

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with ...

LBBB is linked to electrical abnormalities, causing inefficient heart pumping, dilation, and systolic dysfunction. The study found LBBB associated with increased heart failure risk, surpassing other ...